HBsAg is an independent prognostic factor in diffuse large B cell lymphoma patients in rituximab era: result from a multicenter retrospective analysis in China

Medical Oncology - 2014
Zheng Wei1, Shanhua Zou1, Feng Li1, Zhigang Cheng1, Junmin Li2, Jianmin Wang3, Chun Wang4, Fangyuan Chen5, Junning Cao6, Yunfeng Cheng7
1Department of Hematology, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, China
2Department of Hematology, Ruijin Hospital, Shanghai JiaoTong University, School of Medicine, Shanghai, China
3Department of Hematology, Changhai Hospital, Second Military Medical University, Shanghai, China
4Department of Hematology, Shanghai First People’s Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
5Department of Hematology, RenJi Hospital, Shanghai Jiaotong university school of medicine, Shanghai, China
6Department of Medical Oncology, Shanghai Cancer Center, Fudan University, Shanghai, China
7Biomedical Research Center, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, China

Tóm tắt

Từ khóa


Tài liệu tham khảo

Park SC, Jeong SH, Kim J, Han CJ, Kim YC, Choi KS, et al. High prevalence of hepatitis B virus infection in patients with B-cell non-Hodgkin’s lymphoma in Korea. J Med Virol. 2008;80:960–6.

Nath A, Agarwal R, Malhotra P, Varma S. Prevalence of hepatitis B virus infection in non-Hodgkin lymphoma: a systematic review and meta-analysis. Intern Med J. 2010;40:633–41.

Wang F, Xu RH, Han B, Shi YX, Luo HY, Jiang WQ, et al. High incidence of hepatitis B virus infection in B-cell subtype non-Hodgkin lymphoma compared with other cancers. Cancer. 2007;109:1360–4.

Marcucci F, Mele A. Hepatitis viruses and non-Hodgkin lymphoma: epidemiology, mechanisms of tumorigenesis, and therapeutic opportunities. Blood. 2011;117:1792–8.

Engels EA, Cho ER, Jee SH. Hepatitis B virus infection and risk of non-Hodgkin lymphoma in South Korea: a cohort study. Lancet Oncol. 2010;11:827–34.

Chabay P, Lara J, Lorenzetti M, Cambra P, Acosta Haab G, Aversa L, et al. Epstein Barr virus in relation to apoptosis markers and patients’ outcome in pediatric B-cell non-Hodgkin lymphoma. Cancer Lett. 2011;307:221–6.

Wang F, Xu RH, Luo HY, Zhang DS, Jiang WQ, Huang HQ, et al. Clinical and prognostic analysis of hepatitis B virus infection in diffuse large B-cell lymphoma. BMC Cancer. 2008;8:115.

Lim ST, Fei G, Quek R, Lim LC, Lee LH, Yap SP, et al. The relationship of hepatitis B virus infection and non-Hodgkin’s lymphoma and its impact on clinical characteristics and prognosis. Eur J Haematol. 2007;79:132–7.

Pfreundschuh M, Kuhnt E, Trumper L, Osterborg A, Trneny M, Shepherd L, et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol. 2011;12:1013–22.

Coiffier B, Thieblemont C, Van Den Neste E, Lepeu G, Plantier I, Castaigne S, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d’Etudes des Lymphomes de l’Adulte. Blood. 2010;116:2040–5.

Matsue K, Kimura S, Takanashi Y, Iwama K, Fujiwara H, Yamakura M, et al. Reactivation of hepatitis B virus after rituximab-containing treatment in patients with CD20-positive B-cell lymphoma. Cancer. 2010;116:4769–76.

Pei SN, Chen CH, Lee CM, Wang MC, Ma MC, Hu TH, et al. Reactivation of hepatitis B virus following rituximab-based regimens: a serious complication in both HBsAg-positive and HBsAg-negative patients. Ann Hematol. 2010;89:255–62.

Zhang B, Wang J, Xu W, Wang L, Ni W. Fatal reactivation of occult hepatitis B virus infection after rituximab and chemotherapy in lymphoma: necessity of antiviral prophylaxis. Onkologie. 2010;33:537–9.

Fukushima N, Mizuta T, Tanaka M, Yokoo M, Ide M, Hisatomi T, et al. Retrospective and prospective studies of hepatitis B virus reactivation in malignant lymphoma with occult HBV carrier. Ann Oncol. 2009;20:2013–7.

Li X, Liu Z, Cao J, Hong X, Wang J, Chen F, et al. Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in China: a 10-year retrospective follow-up analysis of 437 cases from Shanghai Lymphoma Research Group. Ann Hematol. 2012;91:837–45.

Swerdlow S, Campo E, Harris NL. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2008.

Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649–55.

Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579–86.

Ji D, Cao J, Hong X, Li J, Wang J, Chen F, et al. Low incidence of hepatitis B virus reactivation during chemotherapy among diffuse large B-cell lymphoma patients who are HBsAg-negative/HBcAb-positive: a multicenter retrospective study. Eur J Haematol. 2010;85:243–50.

Huang HH, Xiao F, Chen FY, Wang T, Li JM, Wang JM, et al. Reassessment of the prognostic value of the International Prognostic Index and the revised International Prognostic Index in patients with diffuse large B-cell lymphoma: a multicentre study. Exp Ther Med. 2012;4:475–80.

Crook PD, Jones ME, Hall AJ. Mortality of hepatitis B surface antigen-positive blood donors in England and Wales. Int J Epidemiol. 2003;32:118–24.

Thông tin
Thông tin xuất bản

Medical Oncology

Thông tin tác giả